KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ACM Research (ACMR) Asset Writedowns and Impairment (2023 - 2025)

ACM Research (ACMR) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $8.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 109.42% to $8.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.3 million, a 93.23% increase, with the full-year FY2023 number at $2.7 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $8.0 million for Q3 2025 at ACM Research, up from $1.4 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $8.0 million in Q3 2025 to a low of -$9000.0 in Q1 2025.
  • A 3-year average of $1.8 million and a median of $1.1 million in 2023 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 295.45% in 2024, then tumbled 100.77% in 2025.
  • ACM Research's Asset Writedowns and Impairment stood at $1.1 million in 2023, then soared by 249.59% to $3.8 million in 2024, then skyrocketed by 109.42% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for ACMR's Asset Writedowns and Impairment are $8.0 million (Q3 2025), $1.4 million (Q2 2025), and -$9000.0 (Q1 2025).